| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash, cash equivalents and restricted cash-Consolidated Entity Excluding Variable Interest Entities VIE | 147,531 | 71,370 | 88,706 | NaN |
| Cash, cash equivalents and restricted cash | NaN | NaN | NaN | 129,793 |
| Cash, cash equivalents and restricted cash-Variable Interest Entity Primary Beneficiary | 40,986 | 130,273 | 137,842 | NaN |
| Accounts receivable | 15,685 | 218,871 | 6,824 | 9,699 |
| Available-for-sale securities, at fair value | NaN | NaN | 692,818 | 770,579 |
| Available-for-sale securities, at fair value and short-term investments | 1,595,574 | 714,967 | NaN | NaN |
| Prepaid expenses | 21,721 | 16,053 | 10,933 | 23,692 |
| Other current assets | 18,254 | 22,855 | 13,516 | 13,160 |
| Total current assets | 1,839,751 | 1,174,389 | 950,639 | 946,923 |
| Property, plant and equipment, net | 374,822 | 378,584 | 382,515 | 381,048 |
| Impairment-Licensing Agreements | 0 | 0 | 0 | NaN |
| Gross carrying amount | 24,857 | 24,857 | 24,857 | NaN |
| Accumulated amortization | 18,846 | 18,421 | 17,996 | NaN |
| Impairment | 0 | 0 | 0 | NaN |
| Intangible assets, net | 6,011 | 6,436 | 6,861 | 7,286 |
| Right-of-use assets | 42,794 | 43,361 | 43,891 | 44,002 |
| Other assets | 4,887 | 1,411 | 1,389 | 1,353 |
| Total assets | 2,268,265 | 1,604,181 | 1,385,295 | 1,380,612 |
| Accounts payable | 30,747 | 32,937 | 17,674 | 33,050 |
| Accrued expenses | 76,585 | 130,081 | 90,419 | 64,818 |
| Accrued payroll and benefits | 20,366 | 14,270 | 26,895 | 19,298 |
| Lease liabilities | 7,774 | 7,529 | 7,289 | 7,010 |
| Deferred revenue | 108,543 | 111,933 | 2,399 | 22,979 |
| Credit facility | 40,000 | 40,000 | 40,000 | 40,000 |
| Other liabilities | 11,205 | 10,675 | 10,811 | 7,375 |
| Total current liabilities | 295,220 | 347,425 | 195,487 | 194,530 |
| Lease liabilities, net of current portion | 100,106 | 102,129 | 104,112 | 105,690 |
| Deferred revenue, net of current portion | 48,615 | 53,825 | NaN | NaN |
| Liability related to the sale of future royalties | 383,829 | 374,997 | 367,397 | 360,254 |
| Credit facility, net of current portion | 159,639 | 163,108 | 214,883 | 200,332 |
| Convertible notes, net | 681,940 | NaN | NaN | NaN |
| Total long-term liabilities | 1,374,129 | 694,059 | 686,392 | 666,276 |
| Common stock, 0.001 par value authorized 290,000 shares 143,232 shares issued and 140,571 outstanding as of march 31, 2026 and 138,363 shares issued and 135,702 outstanding as of september 30, 2025 | 236 | 233 | 231 | 230 |
| Additional paid-in capital | 2,395,267 | 2,211,026 | 2,139,725 | 2,120,130 |
| Accumulated other comprehensive income | 742 | 6,699 | 6,443 | 5,357 |
| Accumulated deficit | -1,729,075 | -1,596,343 | -1,627,154 | -1,603,404 |
| Treasury stock at cost 2,661 shares of common stock at march 31, 2026 and september 30, 2025 | 53,193 | 53,193 | 53,193 | NaN |
| Stockholders equity | 613,977 | 568,422 | 466,052 | 522,313 |
| Noncontrolling interest | -15,061 | -5,725 | 37,364 | -2,507 |
| Total noncontrolling interest and stockholders equity | 598,916 | 562,697 | 503,416 | 519,806 |
| Total liabilities, noncontrolling interest and stockholders equity | 2,268,265 | 1,604,181 | 1,385,295 | 1,380,612 |
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
ARROWHEAD PHARMACEUTICALS, INC. (ARWR)